Hearing Expert Linda Gonya-Hartman, Au.D. Shares the Differences Between Professional & Online Hearing Tests in HelloNation

HelloNation published an educational article outlining how professional audiology exams use calibrated equipment to assess hearing thresholds across frequencies, speech understanding, and differences between ears. The article positions online hearing tests as an initial screening tool but says they cannot account for device conditions, personal medical history, or individualized follow-up testing. No financial results, product launch, clinical trial data, or material corporate development was disclosed.

Analysis

This is effectively local paid-content marketing rather than a demand datapoint, so it should not alter healthcare positioning. The only investable read-through is that education-led referrals can marginally improve the conversion funnel from self-screening to clinician-led diagnosis, which favors audiology-channel incumbents such as Sonova (SOON), Demant (DEMANT) and Amplifon (AMP) over direct-to-consumer hearing-device models. That mechanism is slow-moving and unlikely to be measurable before 2027 given appointment capacity, reimbursement friction and the long replacement cycle for hearing aids.

The more relevant competitive issue remains whether OTC hearing aids expand the addressable market or cannibalize professionally fitted premium devices. Greater awareness of the limitations of online screening may support clinic referrals and higher-specification devices, but the article provides no evidence of increased testing volumes, referral rates, unit sales, or pricing. A constructive thesis would be falsified if OTC category growth materially outpaces audiologist-channel volumes for two consecutive quarters, or if Sonova/Demant report deteriorating average selling prices and clinic traffic.

Near term, there is no identifiable catalyst and no reason to trade on this release. Over 6-18 months, investors should monitor US audiology appointment volumes, private-pay versus reimbursed mix, and premium-device ASPs; these are the variables that determine whether consumer awareness converts into incremental industry revenue rather than merely shifting testing methods.

Key Decisions for Investors

• No new position on this release; treat it as non-material promotional content rather than a fundamental catalyst.
• Maintain a watchlist on Sonova (SOON), Demant (DEMANT) and Amplifon (AMP) for quarterly evidence that clinician-channel traffic and premium-device ASPs are accelerating; only consider longs after independently verifiable volume or guidance confirmation.
• For a 6-18 month relative-value framework, prefer SOON or DEMANT versus OTC-exposed consumer-hearing competitors if professional-channel unit growth exceeds OTC growth; invalidate the trade on sustained ASP compression or a material OTC share gain.
• Set an alert for earnings disclosures on US hearing-aid unit growth, audiology staffing/capacity, and reimbursement changes; absent those data, expected risk/reward is insufficient for an actionable sector trade.